BENDITA BEnznidazole New Doses Improved Treatment and Associations
Summary
Recent scientific advances have provided further impetus to develop new therapeutic approaches for Chagas Disease (CD) using different doses and duration of BZN, as well as combinations directed at multiple therapeutic targets to improve treatment response and tolerability and reduce the potential for development of resistance. This project focuses on the proof-of-concept evaluation of improved treatment regimens of BZN, with the assessment of new BZN-sparing regimens in monotherapy and in combination with E1224.
Timeline
- Start
- 2016-11-30
- Primary completion
- 2018-01-28
- Completion
- 2018-07-27
Outcome
Met primary endpoint
paper Sustained parasitological clearance at 6 months was observed in 25 (89%) of 28 patients receiving benznidazole 300 mg daily for 8 weeks PMID 33836161 ↗
paper p<0·0001 for all group comparisons with placebo). PMID 33836161 ↗
paper Benznidazole induced effective antiparasitic response, regardless of treatment duration, dose, or combination with fosravuconazole, and was well tolerated PMID 33836161 ↗
Publications
- Saade U, de Boer J, Scandale I, Altcheh J, Pottel H, Chatelain E, Zrein M. Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay. Nat Commun. 2024 Dec 3;15(1):10530. doi: 10.1038/s41467-024-54910-x.
- Torrico F, Gascon J, Barreira F, Blum B, Almeida IC, Alonso-Vega C, Barboza T, Bilbe G, Correia E, Garcia W, Ortiz L, Parrado R, Ramirez JC, Ribeiro I, Strub-Wourgaft N, Vaillant M, Sosa-Estani S; BENDITA study group. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis. 2021 Aug;21(8):1129-1140. doi: 10.1016/S1473-3099(20)30844-6. Epub 2021 Apr 6.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benznidazole | Small molecule | 150 mg | Oral |
| Subject | Benznidazole | Small molecule | 300 mg | Oral |
| Subject | E1224 | Unknown | 100 mg | Oral |